SaNOtize raised $24M to fund phase 3 trial of COVID-19 nasal spray


SaNOtize has raised a $24 million series B round, giving it the cash to fund its ongoing phase 3 COVID-19 prevention trial and other research into its nitric oxide nasal spray (NONS).  

The Vancouver-based company set up shop in 2017 to unlock the antimicrobial properties of nitric oxide. Using its nitric oxide releasing solution platform, SaNOtize sought to enable the use of the molecule in sprays, baths, lavages, gels and creams. Interest in the platform went up a gear in 2020 when COVID-19 created a pressing need for interventions capable of treating and preventing SARS-CoV-2 infection.
Published bNick Paul Taylor on Aug 30, 2022 09:55am on

Leave a comment

All blog comments are checked prior to publishing
You have successfully subscribed!
This email has been registered